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Relationship between urinary calcium and calcium intake during
calcitriol administration. The hypercalciuria that occurs when 1,25
(OH)2D3 (calcitriol) is given to humans with normal renal function
depends on dietary Ca absorption and may also relate, in part, to
enhanced bone resorption. To evaluate the relationship between uri-
nary and dietary Ca during treatment with calcitriol, 12 metabolic
balance studies were performed in normal volunteers ingesting a diet
containing 350 mg/day of Ca, to which Ca gluconate was added. After
10 days on either 350 mg/day or 1550 mg/day of Ca, calcitriol, 0.5 g
every 12 hr, was given. Then diet Ca was changed in successive 5-day
treatment periods from 350 to 650, 950 and 1550 mg/day (group A) or
from 1550 to 950, 650 and 350 mg/day (group B). On the lowest diet Ca,
urinary Ca was less than Ca intake during calcitriol treatment (group A,
220 50 mg/day; group B, 247 40). As diet Ca was changed during
calcitriol treatment, urinary Ca correlated with diet Ca (r = 0.60) until
diet Ca reached 950 mg/day. With calcitriol, serum iPTH fell by 18 to
25% (P < 0.01) and urinary hydroxyproline fell by 11 to 19% (P < 0.05
to 0.01). Baseline serum levels of 1,25(OH)2D were 47 8 and 34 5
pg/mi in group A and B, respectively, and the values increased to 51
12 and 45 7.4 pg/mI during treatment with calcitriol. Serum Ca from
fasted subjects was not affected by calcitnol, but the mean postabsorp-
tive serum Ca (noon) was increased by 0.35 mgldl. Although urine
Calcreatinine from fasted subjects increased with calcitriol treatment,
the values varied directly with the 24-hr urine Ca and inversely with
serum iPTH levels. Thus, dietary Ca is the major determinant of urinary
Ca during treatment with calcitriol, and the latter may decrease dietary
Ca requirements. There was no evidence for an increased bone resorp-
tion. The reduction of hydroxyproline excretion suggests that bone
resorption was initially depressed, perhaps due to iPTH suppression.
The data also suggest that urine Calcreatinine after fasting for 12 hr is
influenced by previous dietary Ca intake or intestinal Ca absorption,
perhaps related to changing iPTH levels.
Several disorders of calcium homeostasis are currently
treated with 1,25 dihydroxyvitamin D3 (1,25(OH)2D3) or
calcitriol, The efficacy of this treatment is being evaluated in
other conditions [1—51. Calcitriol is the most potent stimulator
of intestinal calcium absorption [6, 7], but its effects on bone
formation or resorption are less well defined. Adams et al [8]
administered calcitriol to normal volunteers on a very low
calcium diet and found persistent elevation of urinary calcium
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excretion, resulting in a negative calcium balance. This obser-
vation is consistent with an effect of calcitriol to enhance bone
resorption. However, the dose of calcitriol given and its fre-
quency of administration were greater than that which is
necessary to increase intestinal calcium absorption. Thus, the
administration of calcitriol on a less frequent basis has not been
associated with any evidence of bone resorption in subjects on
a normal calcium intake [9].
The present study was undertaken to evaluate the contribu-
tion of differences in dietary calcium intake to changes in
urinary calcium excretion in normal subjects treated with a low,
constant dose of calcitriol. Within the dose range given in this
study, the present observations indicate that the degree of
hypercalciuria relates directly to dietary calcium intake and can
be modified substantially by a reduction in dietary intake. The
data also show that the urinary calcium from fasted subjects can
be modified by dietary calcium intake, an observation casting
some doubt on the value of urine calcium obtained after a 12-hr
fast being a definite indicator of bone resorption or urinary leak
of calcium.
Method
Studies were carried out on nine healthy males and three
females, aged 25 to 63 years. The subjects were studied at the
Clinical Research Center (CRC) at the University of California
Los Angeles Center for the Health Sciences or the Special
Diagnostic and Treatment Unit (SDTU) at the Veterans Admin-
istration Wadsworth Medical Center. Through the entire study,
each subject received a constant nutritionally balanced diet (the
"basic diet") which was restricted in calcium content to 352
15 mg/day (range, 238 to 442 mg/day); the quantities of phos-
phorus and magnesium were 1001 65 and 237 14 mg/day,
respectively.
Two separate protocols were followed: In protocol A, there
was a step-wise increase in dietary calcium, while in protocol B,
the initial diet contained the highest calcium content, followed
by a step-wise decrease in calcium intake to that of the basic
diet. On admission to the study ward, the patients first had an
initial equilibration period of 2 to 3 days, and then entered a
control period (period 1) of 10 days; after this calcitriol was
given in a dosage of 0.5 jg at 8 A.M. and 8 P.M. daily for the
remainder of the study.
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Fig. 1. Representative experiment showing daily urinary calcium excre-
tion (upper panel) in relation to diet calcium (lower panel) in a subject
from protocol A. Dietary calcium was maintained at 350 mg/day for the
first 15 days and then increased to 650, 950, and 1550 mg/day during
successive 5-day periods. The subject was given calcitriol, 0.5 g twice
daily from day 11 until the end of the study. Urinary calcium excretion
increased with calcitriol therapy, with further increases as diet calcium
was raised to 950 mg/day. No further increase in urinary calcium
excretion was observed with a further increment in dietary calcium.
In protocol A, no calcium supplements were given during the
first 15 days of the study (periods 1 and 2). During each
successive 5-day period, the subjects received supplements of
calcium gluconate, providing elemental calcium of first 300
mg/day (period 3), then 600 mg/day (period 4), and finally 1200
mg/day (period 5). During protocol B, the patients received the
basic diet plus a calcium supplement of 1200 mg/day from the
outset. After the 10-day control period (period 1), calcitriol was
given as described above (period 2); then the calcium supple-
ment was reduced to 600 mg/day for 5 days (period 3), then to
300 mg/day for the next 5 days (period 4), and finally withdrawn
for the finalS days (period 5). Examples of the two protocols are
shown in Figures 1 and 2.
During the periods with calcium supplementation, calcium
gluconate was given in divided doses at 8 A.M., 10 A.M., 12
P.M., 2 P.M., and 4 P.M. In one subject, the study was carried
out utilizing 8-day rather than 5-day periods to assess the
adequacy of the 5-day periods with the changing calcium intake
(Fig. 2). During each period with the same calcium intake there
was no difference between the mean urinary calcium on days 6,
7, and 8 compared to that on days 3, 4, and 5.
Blood samples were obtained daily while patients were in the
fasting state at 7 A.M., and also before the noon meal on the last
3 days of each study period. Twenty-four hour urine specimens
were collected daily throughout the study and from 6 to 8 A.M.
on the last 3 days of each dietary period after a 12-hr fast.
Aliquots of each 24-hr urine specimen were analyzed for
calcium, phosphorus, magnesium, sodium, hydroxyproline,
and creatinine. Calcium, phosphorus, magnesium, and creati-
nine were measured in the 2-hr fasting urine samples. In the
serum samples obtained from fasted subjects, calcium, phos-
phorus, magnesium, creatinine, immunoreactive parathyroid
hormone (iPTH), and 1 ,25(OH)2D levels were measured. Cal-
cium, iPTH and 1 ,25(OH)2D levels were determined in the noon
samples.
Creatinine and phosphorus were determined using standard
autoanalyzer techniques, sodium by flame photometry, and
calcium and magnesium by atomic absorption spectroscopy; all
methods were reported previously [6]. Serum iPTH was mea-
sured by a radioimmunoassay utilizing antiserum Ch-9, sup-
plied by Dr. Eduardo Slatapolsky, Washington University
School of Medicine, St. Louis, Missouri, which is directed
toward the mid-carboxy terminal fragment of PTH [10]. Urinary
hydroxyproline was determined by the method of Blumen-
krantz and Asboe-Hansez [11], and serum levels of 1 ,25(OH)2D
were determined by a competitive binding assay following
separation with Sephadex chromatography. With this method,
intra-assay variation is 11.1% and interassay variation 18.1%
30 [12]. All measurements for each patient were performed in a
single assay to avoid interassay variations. For calculation of
the data, the values from both serum and urine over the last 3
days of each period were averaged. Statistical comparisons
utilized the paired t test for observations in the same patient and
nonpaired t test or linear regression analysis for other compar-
isons [13].
Results
Examples of urinary calcium excretion in individual subjects
who followed protocol A or B are shown in Figures 1 and 2,
respectively. The overall mean values of serum and urine
biochemical parameters are given in Table 1. During protocol
A, the addition of calcitriol to the basic diet containing 350 mg
of calcium/day caused an immediate increase in urinary cal-
cium; however, the total 24-hr calcium excretion remained
lower than dietary calcium intake in all subjects except one, a
patient with a calcium excretion of 322 mg/day before calcitriol
treatment. As the total dietary calcium intake was increased to
650 and then to 950 mg/day, there were further increments in
urinary calcium. However, there was no further increase in
urinary calcium as total calcium intake increased from 950 to
1550 mg/day. The mean changes in urinary calcium as the
subjects changed from one dietary period to the next are shown
in Figure 3. Total 24-hr urinary calcium increased by 93 21
mg/day when calcitriol was added to the basic diet; further
increases in calcium intake to 650 and then to 950 mg/day
produced further increases of 151 19 and 105 56 mg/day,
respectively, above the previous diet. There were no changes in
the mean levels of serum calcium or phosphorus from fasted
subjects; however, the serum magnesium level decreased sig-
nificantly with the addition of calcitriol, particularly during the
periods with total calcium intakes of 350 and 650 mg/day. There
were no significant changes in urinary phosphorus excretion;
urinary magnesium excretion rose slightly, and the values were
significantly greater than control. When dietary calcium was
increased to 650 mg/day (period 2), there was a significant
decrease in serum iPTH, and the values tended to remain lower
than control throughout the remainder of the study. When
calcitriol was added, urinary hydroxyproline also decreased
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Table 1. Serum biochemical data, immunoreactive parathyroid hormone (iPTH) and calcitriol [l,25(OH)2D] levels, urinary excretion of minerals and
hydroxyproline (OHPro), and creatinine clearance (Ca) in normal subjects receiving varying calcium intakes with calcitriola
Period
Diet Ca
mg/day
Calcitriol
dosage
xgIday
Serum
Ca P Mg
1,25(OH)2D
pg/mimgld!
Protocol A
1 350 0 9.4 0.20 3.7 0.15 2.09 0.074 47 7.7
2 350 1.0 9.4 0.18 3.9 0.13 1.93 0.077" 48 4.7
3 650 1.0 9.6 0.13 4.1 0.21 1.90 0.0S31 43 4,7
4 950 1.0 9.6 0.25 4.0 0.27 1.89 0,12 58 20
5 1550 1.0 9.5 0.23 3.9 0.24 1.82 0.12 51 12
Protocol B
1 1550 0 9.4 0.20 3.5 0.12 1.95 0,079 34 4.6
2 1550 1.0 9.5 0.16 3.7 0.13 1.86 0078b 43 49b
3 950 1.0 9.4 0.14 3.6 0.13 1.90 0.052 39 3.5
4 650 1.0 9.5 0.17 3.6 0.11 1.89 0.044 43 5.9
5 350 1.0 9.5 0.12 3.5 0.10 1.96 0.058 45 7.4
a Values are mean SE; for each patient, the data are the mean values over the last 3 days of each diet period; serum values represent fasting
morning results.
Statistically different from period I (baseline) by paired (test: b p < 0.05, P < 0.02, d p < 0.01.
Fig. 2. Representative experiment showing the
daily urinary calcium excretion in relation to
dietary calcium in a subject from protocol B.
Dietary calcium was maintained at 1550 mg/day
for the first 15 days and then decreased to 950,
650, and 350 mg/day during successive 8-day
periods. The subject was started on calcitriol, 0.5
g twice daily on day 11 and treatment was
continued for the duration of study. Urinary
calcium excretion increased after initiation of
calcitriol treatment and remained elevated until
diet calcium was lowered from 650 to 350
mg/day.
slightly, and the values were significantly lower than control
during periods 2 and 3.
When calcitriol treatment was added to the high calcium
intake in protocol B and there was a progressive reduction in
calcium intake, the pattern of urinary calcium excretion differed
from that in protocol A (Fig. 3). With the addition of calcitriol
during period 2, urinary calcium increased by 156 39 mg/day.
However, as the calcium intake was reduced from 1550 to 950
and then 650 mg/day, urinary calcium did not change signifi-
cantly. As dietary calcium was lowered from 650 to 350 mg/day
in period 5, urinary calcium did significantly decrease by 69
19 mg/day. As in protocol A, there were no changes in serum
calcium and phosphorus levels from fasted subjects during
calcitriol treatment or with the changes in calcium intake. There
was a small but significant decrease in serum magnesium levels
with calcitriol treatment during period 2 and urinary magnesium
increased slightly and significantly during periods 3 and 4.
Urinary hydroxyproline excretion tended to be lower, but this
did not reach statistical significance. Urinary phosphorus ex-
cretion was unchanged.
The data for urinary calcium and magnesium after a 12-hr
fast, calculated as calcium/creatinine and magnesiumlcreatinine
ratios and the theoretical phosphate threshold (TmPO4/GFR),
are given in Table 2. During calcitriol treatment in both proto-
cols A and B, there were increments in the urinary
calciumlcreatinine ratios which were of greater statistical sig-
nificance during protocol A. There was a significant correlation
between the urinary calcium/creatinine ratios and the total 24-hr
urinary calcium excretion (Fig. 4). Moreover, urinary
calcium/creatinine from fasted subjects showed an inverse
correlation with the changes in serum iPTH, as shown in Figure
5. The urinary magnesiumlcreatinine ratio tended to be lower
during calcitriol administration, but this was significant only
during period 4 of protocol A. There was a tendency for the
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Table 1. Continued
Serum
iPTH
islEq/ml
Urine
Ccr
ml/min/1.73 m2
Ca P Mg
OHPro
rsg/mg creatmg/day
6.1 0.61 127 38 694 51 134 7 19.0 2.4 111.46 7.37
4.8 0•63d 220 50d 681 55 141 13 17.0 2.4 111,69 8.43
4.4 0.44c 361 50d 718 64 152 9" 18.0 0.7" 114.87 5.76
5.1 0.57 501 82' 621 62 130 6 16.0 2.2 111.84 10.0
5.2 0.66 498 60" 566 65 129 12 13.0 5.4 104.56 8.26
6.4 0.80 167 18 522 53 117 13 16.8 2.7 98.76 3.62
4.9 0.56 323 55' 475 47" 126 16 13.8 0.91 92.58 3,08
5.4 0.50 357 48" 555 59 131 16" 13.5 2.1 96.67 2,61
5.2 0.45 316 55C 660 90 132 l2 14.0 1.5 94.30 2.69
5.1 0.45 247 40b 641 60 120 13 13.8 0.90 95.15 3.22
Discussion
The present studies in normal subjects ingesting a known
dietary calcium intake and a constant dose of calcitriol show a
close relationship between total urinary calcium excretion and
dietary calcium intake. This relationship was apparent when
dietary calcium was increased from 350 to 950 mg/day or
decreased from 950 to 350 mg/day. From these results, it
appears that a major component of urinary calcium excretion
during calcitriol therapy is of dietary origin and that urinary
calcium can therefore be modified by manipulation of dietary
calcium.
The present studies confirm that calcitriol can markedly
increase urinary calcium excretion and suggest that calcitriol
p
can significantly reduce the minimum dietary requirement for
calcium. In both dietary groups, urinary calcium excretion
increased alter giving the subjects calcitriol, 0.5 g twice a day,
with a stable intake of dietary calcium. This increase in urinary
calcium excretion with calcitriol therapy represents enhanced
intestinal absorption of calcium in addition to suppression of
PTH secretion. Treatment of subjects receiving 350 mg per day
of dietary calcium with 0.5 sg twice daily of calcitriol increased
calcium absorption by 80 to 100 mg per day as suggested by the
increase in urinary calcium. Thus, urinary excretion of subjects
receiving calcitriol and a diet providing 350 mg of calcium was
about 238 mg per day. This is a very similar observation to a
study by Spencer et al [14] who gave subjects 2300 mg per day
of dietary calcium.
The biological effect of calcitriol to increase urinary calcium
appears to reach a steady state after 3 to 5 days as shown
previously from this laboratory [1] and confirmed in the present
study. The subsequent increase in urinary calcium observed
with a step-wise increase in dietary calcium would therefore
appear to be primarily of dietary origin. Other factors which
could have contributed to a delayed increase in urinary calcium
excretion include a greater intestinal absorption of calcium by
stimulation of the growth of intestinal mucosa by calcitriol [15],
and/or a delay in the suppression of PTH levels by calcitriol, per
se [16—20]. Little is known regarding the dose requirement for
these effects or their biological half-lives [19]. It is possible that
the delay in achieving a steady state with higher doses of
calcitriol [21] could have arisen due to mucosal growth [15] or
from recruitment of additional segments of the intestine [22].
Even if these factors may have accentuated the increase in
urine calcium from subjects in protocol A as dietary calcium
was increased, they did not prevent the decline in urine calcium
from subjects in protocol B as dietary calcium was decreased
from 950 to 350 mg per day, emphasizing the important contri-
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Fig. 3. Mean changes in urinaly calcium excretion in relation to dietary
calcium in subjects in groups A (•) andB (•). The data are shown as
the mean SEM, N = 4—6. The change in urinary calcium excretion was
calculated as the difference between the urinary calcium excretion
obtained during each treatment period and baseline. Symbols are: ", P
<0.05; **, p < 0.02; '"K, p < 0.01 for the difference compared to the
preceding period by paired t test.
TmPOIGFR to increase during treatment with calcitriol; how-
ever, this increase reached statistical significance only during
period 2 of protocol B.
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Table 2. Urinary calciumlcreatinine and magnesium/creatinine ratios and TmPO,4/GFR in fasted subjects receiving varying calcium
intakes with calcitriola
Period
.Diet Ca
mg/day
.Calcitnol dosage
pg/day
CalCreat Mg/Creat
TmPOIGFR
mg/dlmg/mg
Protocol A
1 350 0 0.06 0.018 0.067 0.01 3.65 0.19
2 350 1.0 0.09 0•018d 0,051 0.004 3.94 0.20
3 650 1.0 0.12 0,022b 0.051 0.007 3.85 0.27
4 950 1.0 0.14 0012b 0.041 0,007d 3.89 0.40
5 1550 1.0 0.13 0.0034 0.037 0.008 4.00 0.28
Protocol B
1 1550 0 0.070 0.014 0.064 0.014 3.3 0.11
2 1550 1.0 0.12 0.0l6 0.057 0.016 3.9 0.16c
3 950 1.0 0.10 0.020 0.055 0.014 3.7 0.29
4 650 1.0 0.12 0.016 0.054 0.013 3.7 0.16
5 350 1.0 0.10 0.017 0.049 0.014 3.7 0.24
a Values are mean sa; for each patient, the data are mean values over the last 3 days of each diet period; serum values represent morning
results after fasting.
Statistically different from period 1 (baseline) by paired t test: ' F C 0.05, F C 0.02, d F C 0.01.
Urinary calcium. mg/24 hr
Fig. 4. Relationship between urinary calcium/creatinine from fasted
subjects and 24-hr urinary calcium excretion in individual subjects
following protocols A (S) and B (0). Each point represents the mean of
values obtained on the last 3 days of a treatment period for a single
subject. Two-hour urine calciumlcreatinine from fasted subjects varied
directly with the 24 hr urinary calcium, F C 0.01.
[15].
When dietary calcium was increased above 950 mg/day, the
correlation between calcium intake and urinary calcium excre-
Change in serum iPTH, u/Eq/mi
Fig. 5. Relationship between the change in urine calcium/creatinine
ratio after a 12-hr fast and the change in serum i-PTH in all subjects in
both protocol A (X) and B (0). Each value represents the difference
between the levels obtained during each treatment period and that
obtained during baseline for each individual. Urinary calcium/creatinine
varied inversely with changes in i-PTH, P C 0.02.
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bution of diet calcium to urinary calcium excretion with
calcitriol administration.
The possibility that this dosage of calcitriol could enhance
bone resorption, the biological half-life of which may be pro-
longed, must be considered, as this could result in a delayed
increase in calcium excretion. Several observations in the
present study make this unlikely, including the direct correla-
tion observed between dietary calcium intake and calcium
excretion as well as the decrease in urinary hydroxyproline
excretion, a presumed marker of bone resorption [23]. Higher
doses of calcitriol when given to normal subjects ingesting an
artificial diet containing only 168 mg (4.1 mM/day) of calcium
per day have been shown to cause a negative calcium balance
tion was lost, whether the subjects received initially the low or
high diet calcium. The explanation for this observation is not
readily apparent from this study but a similar observation was
made by Spencer et a! [14]. If urinary calcium is primarily of
dietary origin, one would have expected urinary calcium to
increase linearly as dietary calcium was increased due to the
diffusion of calcium across the intestinal mucosa, One possibil-
ity is that the calcium transport sites in the intestine that are
activated by calcitriol become saturated with the high dietary
calcium. Another possible explanation comes from studies in
several epithelial tissues, including the intestine, which have
shown that high concentrations of divalent cations can alter
paracellular channels and retard transport via this pathway [24j.
Whether the high concentrations of calcium in the intestinal
Calcium and calcitriol administration 583
lumen may have been sufficient to alter diffusion across the
intestine with the highest dietary calcium is a possibility, but
this remains conjectural.
Finally, the present observation of a close relationship be-
tween the calciumlcreatinine ratio from fasted subjects and the
total daily urinary calcium excretion during therapy with
calcitriol casts doubt on the value of absolute measurements of
urinary calciumlcreatinine after a 12-hr fast to indicate either
bone resorption or a renal leak of calcium [251. The inverse
correlation found between the changes in urinary calciumicre-
atinine and the changes in serum iPTH suggest that alterations
in dietary calcium can alter urinary calcium/creatinine after a
12-hr fast through the effect of a high dietary calcium to
suppress serum iPTH, similar to the observations of Tieder et al
[261. This would suggest that the renal effect of PTH to augment
tubular reabsorption of calcium is more dominant in modifying
urine calcium in fasted normal subjects than is the effect of PTH
on bone. Moreover, the current observations suggest that the
urinary calcium/creatinine ratio from fasted subjects may in-
deed provide a useful index to monitor calcitriol therapy in
patients with intact renal function.
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